Skip to main content
INMB
NASDAQ Life Sciences

MHRA Approves INmune Bio's CORDStrom™ Pediatric Plan Ahead of Schedule, Accelerating UK Market Path

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.494
Mkt Cap
$35.89M
52W Low
$1.09
52W High
$11.64
52W Position info
37% above low
Off High info
87% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

INMB sits 37% above its 52-week low of $1.09.

Summary

INmune Bio received MHRA approval for its Pediatric Investigation Plan (PIP) for Ebstrocel™ (CORDStrom™) in the UK, a critical step towards market authorization for Recessive Dystrophic Epidermolysis Bullosa (RDEB). This approval was granted in under three months, significantly faster than anticipated, and provides a clear roadmap for a planned 2026 Marketing Authorization Application. This regulatory de-risking event is highly positive for the small-cap biotech, especially given its recent "going concern" warning. The company aims for a UK MAA filing in 2026 and a US Accelerated Approval filing in early 2027.

At the time of this announcement, INMB was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.9M. The 52-week trading range was $1.09 to $11.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

INMB - Latest Insights

INMB
Nov 05, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.819 info
Change: -$0.356 (-30%) info
Market Cap: $25.355M info
INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.819 info
Change: -$0.701 (-46%) info
Market Cap: $25.355M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.819 info
Change: -$0.591 (-42%) info
Market Cap: $25.355M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.819 info
Change: -$0.870 (-52%) info
Market Cap: $25.355M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.819 info
Change: -$0.811 (-50%) info
Market Cap: $25.355M info